Artugen is harnessing recent advances in microbiome science to identify novel Live Biotherapeutic Products to help patients living with infectious, inflammatory and oncologic diseases
Our Mission
Artugen is committed to developing Live Biotherapeutic Products to prevent and treat various human diseases.
Our Platform
Artugen identifies, characterizes and manufactures naturally occurring bacteria possessing biological properties to drive beneficial pharmacologic outcomes.
Our Aim
Artugen strives to identify novel therapies to help patients living with infectious, inflammatory and oncologic diseases.
News & Publications
Artugen Therapeutics Announces First Patient Dosed with ART24
March 12, 2020 Artugen’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection - ART24 granted Fast Track Designation - First Patient Dosed
NIH: “Probiotic bacteria block harmful microbe”
NIAID Director Dr. Anthony S. Fauci talks about the use of bacteria as drugs.
CDC: 2019 AR Threats Report
A newly published CDC report includes the latest national death and infection estimates that underscore the continued threat of CDI in the U.S.
Tackling the biggest global health threats
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world.
Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such as organ transplantations, chemotherapy and surgeries such as caesarean sections become much more dangerous.
The Artugen team has discovered and is developing a novel oral Live Biotherapeutic Product for the prevention of C. difficile infection recurrence.
Have a question?
Interested in collaborating with us?